Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acarbose
Drug ID BADD_D00018
Description Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued).[L31668] This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal adverse effects.[L31668]
Indications and Usage Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[L31628]
Marketing Status approved; investigational
ATC Code A10BF01
DrugBank ID DB00284
KEGG ID D00216
MeSH ID D020909
PubChem ID 444254
TTD Drug ID D0AD5C
NDC Product Code 72789-133; 65897-1005; 42291-131; 62135-453; 0054-0142; 71335-1583; 72789-131; 52972-0035; 23155-149; 42291-130; 63629-5698; 69543-122; 71335-9725; 64380-758; 71205-854; 62135-454; 64380-759; 64380-760; 72789-132; 50090-4952; 69543-120; 69543-121; 42513-0016; 42291-132; 62135-455; 0054-0140; 58623-0022; 65897-4005; 71052-656; 23155-148; 71205-856; 23155-147; 0054-0141; 71205-855; 43353-951
UNII T58MSI464G
Synonyms Acarbose | Glumida | Glucobay | Glucor | Bay g 5421 | Prandase | Precose
Chemical Information
Molecular Formula C25H43NO18
CAS Registry Number 56180-94-0
SMILES CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.002709%
Abdominal pain07.01.05.0020.001084%
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.0010.001084%-
Asthenia08.01.01.0010.001625%-
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.0020.001084%-
Constipation07.02.02.001--
Cough22.02.03.0010.002167%
Death08.04.01.001--
Dehydration14.05.05.0010.001625%
Dermatitis23.03.04.002---
Diabetic ketoacidosis05.07.03.001; 14.07.03.0010.001084%-
Diarrhoea07.02.01.0010.006176%
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.007043%
Drug ineffective08.06.01.0060.012894%-
Dyspepsia07.01.02.001--
Erythema23.03.06.001---
Flatulence07.01.04.0020.002384%
Gastrointestinal disorder07.11.01.0010.004009%-
Gastrointestinal pain07.01.05.005--
Hepatic function abnormal09.01.02.001---
Hepatitis09.01.07.004---
Hepatitis fulminant09.01.07.007; 11.07.01.003---
Hepatocellular injury09.01.07.008---
Hyperhidrosis08.01.03.028; 23.02.03.0040.001084%
Hypersensitivity10.01.03.003--
Hypoglycaemia05.06.03.001; 14.06.03.0010.006934%
Hypoglycaemic coma05.06.03.004; 14.06.03.004; 17.02.09.0050.002167%-
Ileus07.13.01.001--
Immune system disorder10.02.01.001---
Intestinal obstruction07.13.01.002---
The 1th Page    1 2 3    Next   Last    Total 3 Pages